logo-loader
viewArix Bioscience PLC

Arix Bioscience investee company Autolus publishes encouraging additional data from blood cancer drug study

The updated data continue to support “early indications of durability and high level of activity previously reported”, Autolus said

Cancer cell
The initial clinical readout from the trial revealed “encouraging clinical activity with a manageable safety profile”

Arix Bioscience PLC (LON:ARIX) said investee company Autolus Therapeutics PLC (NASDAQ:AUTL) has published encouraging additional data from its phase I/II clinical study of a drug developed to treat a type of blood cancer called diffuse large B cell lymphoma.

AUTO3 is a next-generation programmed T cell therapy that is being trialled in people with relapsed or refractory (difficult to treat) forms of the disease.

The initial clinical readout from the trial revealed “encouraging clinical activity with a manageable safety profile”. The updated data continue to support “early indications of durability and high level of activity previously reported”, Autolus said in its statement.

The new information will be presented in full later today (Thursday, Jan 30) by Dr Martin Pulé, chief scientific officer of Autolus, at the EHA-EBMT 2nd European CAR T Cell Meeting held in Stiges, Spain.

Quick facts: Arix Bioscience PLC

Price: 86.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £117.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read